Pacira BioSciences (NASDAQ:PCRX - Get Free Report) announced its earnings results on Tuesday. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01, Briefing.com reports. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company had revenue of $181.10 million during the quarter, compared to analyst estimates of $183.11 million. During the same period in the previous year, the business earned $0.96 earnings per share. The firm's quarterly revenue was up 1.7% compared to the same quarter last year. Pacira BioSciences updated its FY 2025 guidance to EPS.
Pacira BioSciences Trading Up 5.9%
PCRX stock traded up $1.41 during trading on Friday, reaching $25.18. The company had a trading volume of 1,207,511 shares, compared to its average volume of 739,942. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $27.64. The company has a market cap of $1.13 billion, a P/E ratio of -9.06 and a beta of 0.48. The business has a 50 day moving average of $23.59 and a 200 day moving average of $24.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.99.
Analyst Ratings Changes
Several analysts have issued reports on the stock. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price target for the company in a research report on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $25.75.
Check Out Our Latest Stock Report on Pacira BioSciences
Insider Transactions at Pacira BioSciences
In related news, SVP Lauren Riker sold 5,578 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the transaction, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Pacira BioSciences
A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company's stock valued at $677,000 after purchasing an additional 1,165 shares in the last quarter. Strs Ohio bought a new position in shares of Pacira BioSciences during the first quarter valued at approximately $75,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Institutional investors own 99.73% of the company's stock.
About Pacira BioSciences
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Stories
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
